| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 05/05/2010 | CN101065120B 4-hydroxy tamoxifen gel formulations |
| 05/05/2010 | CN101039944B 1,5-naphthyridine azolidinones having CDK1 antiproliferative activity |
| 05/05/2010 | CN101039681B Intestinal polyp inhibitor |
| 05/05/2010 | CN101031312B Anti-cancer compositions containing a shark meat extract and a mushroom extract |
| 05/05/2010 | CN101023079B Substituted hydantoins for the treatment of cancer |
| 05/05/2010 | CN101001629B Medicinal composition |
| 05/04/2010 | US7709664 E.g., 3-arylmethyl-7-hydroxy-coumarins as intermediates; affects both the Tumor Necrosis Factor alpha level and transcription activity of NuclearFactor kappa Beta; antiimmunoinflammatory agents and autoimmune properties; antiarthritis agents; rheummatic diseases; osteoporosis; leukemia |
| 05/04/2010 | US7709640 Inhibitors of phosphorylation of platelet derived growth factor receptor |
| 05/04/2010 | US7709621 Vectors with modified protease-dependent tropism |
| 05/04/2010 | US7709535 Androgen receptor antagonists; certain cancers such as colon, skin and prostate cancer, baldness, hirsutism, behavioral disorders, acne, and inhibition of spermatogenesis if so desired |
| 05/04/2010 | US7709526 Use of cyclolignans and new cyclolignans |
| 05/04/2010 | US7709520 Diindolylmethane and C-substituted diindolylmethane compositions and methods for the treatment of multiple cancers |
| 05/04/2010 | US7709519 2-(1,3-Dihydro-2H-benzimidazol-2-ylidene)-1-[3-(1,2-dihydroxyethyl)phenyl]-3-(3,4,5-trifluorophenyl)propane-1,3-dione; GnRH receptor antagonism; prostate cancer, breast cancer, endometriosis, uterine leiomyoma, benign prostatic hypertrophy; good availability by oral administration |
| 05/04/2010 | US7709515 Therapy for cardiovascular disorders; dyslipidemia; glucose metabolism disorders; Alzheimer's disease |
| 05/04/2010 | US7709514 benzimidazole-2-one-5-n-pentanoate; inhibiting Macrophage Migration Inhibitory Factor (MIF); rheumatoid arthritis |
| 05/04/2010 | US7709506 Kinase inhibitors to mediate disease and as antiinflammatory agents |
| 05/04/2010 | US7709500 Chemical compounds |
| 05/04/2010 | US7709493 Tryptophan hydroxylase inhibitors; anticarcinogenic agents; gastrointestinal, cardiovascular, and respiratory system disorders; (S)-2-amino-3-[4-(2-amino-6-{R-1-[4-chloro-2-(3-methyl-pyrazol-1-yl)-phenyl]-2,2,2-trifluoro-ethoxy}-pyrimidin-4-yl)-phenyl]-propionic acid ethyl ester |
| 05/04/2010 | US7709489 e.g. 1-(9-Benzylamino-10-cyano-imidazo[1,2-a]quinoline-2-carbonyl)-4-methylpiperazine; cardiovascular diseases; acylation of imidazo[1,2- alpha]quinoline acid derivatives by morpholine derivatives |
| 05/04/2010 | US7709487 Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
| 05/04/2010 | US7709486 antiviral compounds 1,4,8,11-tetraazacyclotetradecane derivatives for against HIV-infected cells, to inhibit the binding by the natural ligand to its chemokine receptor; viricides |
| 05/04/2010 | US7709480 2-(3,4-dichlorophenylamino)-4-thiocyanato-5-nitro-pyrimidine; 2-chloro-4-(2-acetylamino-ethylamino)-5-trifluoromethyl-pyrimidine; lung cancer |
| 05/04/2010 | US7709479 Quinazoline derivatives and their use as pharmaceuticals |
| 05/04/2010 | US7709478 Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amines and their use as pharmaceutical agents |
| 05/04/2010 | US7709460 co-administration of a glutathione precursor (N-acetyl cysteine or alpha -lipoic acid) and hydroxocobalamin (a derivative of Vitamin B12) to patients with a functional Vitamin B12 deficiency and suffering from a neuropsychiatric abnormality |
| 05/04/2010 | US7709457 treating bladder cancer; transfecting with polynucleotide into urothelial cells; improved transfection efficiency with cationic lipids, cationic polymers or dendrimers; improve drug delivery with a solubilized cholesterol |
| 05/04/2010 | US7709255 Nerve cells obtained by the method of the present invention have the flexibility to differentiate into a variety of types of neurons in vivo preferably without the need for application of growth factors; Embryonic Stem (ES) cells |
| 05/04/2010 | US7709220 Methods of monitoring treatment of BAFF-R related disease |
| 05/04/2010 | US7709217 Mixture comprising hemopoietic cytokine specific immunnoglobulin for use in detection of infection and immunololgical disorders |
| 05/04/2010 | US7709214 Using antibody specific blocking agents to treat and prevent infection, cell proliferative and immunosuppressive disorders |
| 05/04/2010 | US7709202 Molecular characteristics of non-small cell lung cancer |
| 05/04/2010 | US7709020 Implantable device comprising phosphorus-containing macrolides |
| 05/04/2010 | US7708987 ras-mediated; administering immunosuppressive for immune constituents that may interfere with the systemic delivery of the reovirus; antiproliferative; in the neoplastic cells phosphorylation of PKR is prevented by inactivation or deletion of PKR; antitumor agents |
| 05/04/2010 | CA2476587C Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| 05/04/2010 | CA2462456C Androstane 17-beta-carboxamides as androgen receptor modulators |
| 05/04/2010 | CA2455566C (+)-cycloolivil as antioxidant obtained from stereospermum personatum |
| 05/04/2010 | CA2440419C Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors. |
| 05/04/2010 | CA2437767C Heterocyclic inhibitors of erk2 and uses thereof |
| 05/04/2010 | CA2427608C Condensed pyradizindione derivatives as pde inhibitors |
| 05/04/2010 | CA2414200C Variolin derivatives as anti-cancer agents |
| 05/04/2010 | CA2399196C Pyrimidine compounds |
| 05/04/2010 | CA2385817C Substituted pyridines and pyridazines with angiogenesis inhibiting activity |
| 05/04/2010 | CA2367636C Fusion proteins |
| 05/04/2010 | CA2347981C Process for the manufacturing of alkaline salts of substituted sulphinyl compounds and products prepared thereby |
| 05/04/2010 | CA2335364C Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| 05/04/2010 | CA2282439C Formulations for hydrophobic pharmaceutical agents |
| 05/04/2010 | CA2281920C Compositions and methods for modulating cellular nf-.kappa.b activation |
| 05/03/2010 | CA2684177A1 Pharmaceutical composition for preventing and treating cancer and health food containing the same for preventing and treating cancer |
| 04/29/2010 | WO2010048623A2 Medical and imaging nanoclusters |
| 04/29/2010 | WO2010048530A2 Methods and compositions employing an iip45 targeting ligand |
| 04/29/2010 | WO2010048452A2 Polycyclic compounds and methods related thereto |
| 04/29/2010 | WO2010048298A1 Combination therapy with peptide epoxyketones |
| 04/29/2010 | WO2010047663A1 Use of tocotrienol composition for the prevention of cancer |
| 04/29/2010 | WO2010047611A1 Process for preparing chlorins and their pharmaceutical uses |
| 04/29/2010 | WO2010047607A2 Method of production of polyanionic drug-carrier conjugates |
| 04/29/2010 | WO2010047509A2 Anti-dr5 antibody with improved affinity and stability, and composition for cancer prevention or treatment including same |
| 04/29/2010 | WO2010047310A1 Tumor antigen peptide and use thereof |
| 04/29/2010 | WO2010047127A1 PHENANTHROINDOLIZIDINE COMPOUND AND NFκB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT |
| 04/29/2010 | WO2010047126A1 PHENANTHROINDOLIZIDINE DERIVATIVE AND NFκB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT |
| 04/29/2010 | WO2010047094A1 Rotaxane compound and antitumor agent |
| 04/29/2010 | WO2010047062A1 Rab6kifl/kif20a epitope peptide and vaccines containing the same |
| 04/29/2010 | WO2010047028A1 Screening method of anti-lung or esophageal cancer compounds |
| 04/29/2010 | WO2010046835A1 Crystalline forms of (r) -5- [3-chloro-4- ( 2, 3-dihydroxy-propoxy) -benz [z] ylidene] -2- ( [z] -propylimino) -3-0-tolyl-thiazolidin-4-one |
| 04/29/2010 | WO2010046791A1 Phosphodiestarase inhibitors |
| 04/29/2010 | WO2010046628A1 Compounds |
| 04/29/2010 | WO2010046540A1 Nucleic acid binding peptide |
| 04/29/2010 | WO2010046338A1 Composition for targeting dendritic cells |
| 04/29/2010 | WO2010046039A1 Mycobacterium tuberculosis vaccine |
| 04/29/2010 | WO2010046035A1 Sulfoximine-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as medicine |
| 04/29/2010 | WO2010046034A1 Sulfone-substituted anilinopyrimidine derivatives as cdk inhibitors, the production thereof, and use as a medicine |
| 04/29/2010 | WO2010046013A1 Azaindole derivative |
| 04/29/2010 | WO2010045896A2 Polymeric composition with synergistic effect in treatment of tumour diseases |
| 04/29/2010 | WO2010045674A1 Methods for inducing programmed cell death |
| 04/29/2010 | WO2010027279A3 Compositions and methods for the treatment and prevention of neoplastic disorders |
| 04/29/2010 | WO2010017317A3 Use of mtor inhibitors to enhance t cell immune responses |
| 04/29/2010 | WO2010014814A3 Glycosylated warfarin analogs and uses thereof |
| 04/29/2010 | WO2010014253A3 Ant4 inhibitor compounds and methods of use thereof |
| 04/29/2010 | WO2010011994A3 Polypeptides and uses thereof |
| 04/29/2010 | WO2010011856A3 Stereospecificity of methylsulfinyl reduction |
| 04/29/2010 | WO2010011772A3 Tri-cyclic pyrazolopyridine kinase inhibitors |
| 04/29/2010 | WO2010011683A3 Methods for the cytological analysis of cervical cells |
| 04/29/2010 | WO2010008852A9 Methods of trea fing λλd methods of diagnosing an immunoproliferative disorder |
| 04/29/2010 | WO2010007316A3 Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as met inhibitors |
| 04/29/2010 | WO2010006189A3 Small-molecule inhibitors of hif and angiogenesis |
| 04/29/2010 | WO2010005799A3 Novel acetates of 2-deoxy monosaccharides with anticancer activity |
| 04/29/2010 | WO2010004204A3 Fgf-r4 receptor-specific antagonists |
| 04/29/2010 | WO2010003475A3 Novel pyrrolidone derivatives for use as metap-2 inhibitors |
| 04/29/2010 | WO2009154835A3 Compositions and methods related to mir-16 and therapy of prostate cancer |
| 04/29/2010 | WO2009143246A3 Arylsulfonamide compounds, compositions and methods of use |
| 04/29/2010 | WO2009135939A3 Pm02734 for use in the treatment of ewing' s sarcoma, osteosarcoma, rhabdomyosarcoma and medulloblastoma |
| 04/29/2010 | WO2009117277A3 Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| 04/29/2010 | WO2009073147A3 Process for preparing bis(thiohydrazide amides) |
| 04/29/2010 | WO2009026446A8 Hdac inhibitors |
| 04/29/2010 | WO2009024763A3 Combination therapy |
| 04/29/2010 | WO2008146911A9 Antibody directed against il13ra2, and diagnostic/therapeutic agent comprising the antibody |
| 04/29/2010 | US20100105953 Human Adam-10 Inhibitors |
| 04/29/2010 | US20100105946 Hydrolytically Degradable Carbamate Derivatives of Poly(Ethylene Glycol) |
| 04/29/2010 | US20100105922 Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 04/29/2010 | US20100105915 Chemokine receptor binding heterocyclic compounds |
| 04/29/2010 | US20100105776 Use of malachite green in the form of drug for treating malignant neoplasms |